We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella
Ruella Lab is proud to support @MarcoRuella as a 2026 Visionaries of the Year candidate for Blood Cancer United!
Advancing therapies for blood cancers is at the heart of our work.
Help us reach $50K by June 12—every penny counts.
Donate & share 👇
🔗 https://t.co/6T1YgJGBJr
Great job to our PhD candidate Audrey for the wonderful presentation at @ISCTglobal! Read more about this work in our @ScienceTM publication.
Also great presentation by Dr. Bruce Levine (@BLLPHD), thank you for featuring our work from @CellCellPress@MarcoRuella@PennMedicine
Amazing presentation this morning at CCI, @PennCancer@PennMedCSO!
• @MarcoRuella presented correlative data from the Phase 1 Senza5-CAR5 study;
• @LemoineJean6 introduced a novel CAR T-cell design targeting IGHV1-69 on B-cell receptors.
Proud to help develop next-gen CAR T!
🗞️📸🌟🤩Beautiful work led by @BernhardDumoul1 with the team builds a single cell spatial atlas of human DKD using Xenium + CosMx + snRNA-seq. @Nature This is not incremental. This is a new layer of pathology. Diabetic kidney disease (DKD) is still treated as one disease. That is the problem. Patients look similar clinically but behave very differently. We asked: is there a biologically distinct subgroup we are missing?
https://t.co/Au83tayvR9
A celebration dinner for all of our recent accomplishments!
⭐️ 4 publications out so far in 2026
⭐️ 2 covers (@BloodPortfolio Vol 147 Issue 16, and @ScienceTM Vol 18 Issue 835)
And so much more to come!
@MarcoRuella
CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: https://t.co/ALzcTAXHax
‼️Ruella Lab at the Heme Malignancies Research in Progress session!
Presenters:
🩸@Shan_Liu_ discusses how host factors such as diet can modulate responses to CAR T-cell therapy
🩸@paruzzol presents on the decade-long persistence of CAR T-cells
@MarcoRuella@PennMedicine
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: https://t.co/TkReJPJRk3
@ASH_hematology Thank you for highlighting our lab! This snapshot is just one small piece of the broader effort that keeps hematology strong and advancing—especially in challenging times.
When political threats put scientific research at risk, your support of the ASH Foundation helped keep hematology vibrant and rewarding. Thank you for driving positive change in hematology. View the 2025 ASH Annual Report: https://t.co/D0VJB410J2
#Fight4Hematology
New research out @CellCellPress in finds that β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer ft. @Shan_Liu_ & @RuellaLab (@PennCancer) https://t.co/6aAq13Wyfl
CAR T cell therapy has shown strong results against certain cancers, but metabolic exhaustion limits its effectiveness over time.
In @CellCellPress, the @MaayanLevyPhD & @ChristophThaiss labs report that a common supplement can fuel CAR T cells to fight cancer more effectively.
Excited to share our new paper in @CellCellPress with @MarcoRuella, led by @Shan_Liu_
and @PuneethGuru_. CAR T cell therapy loses effectiveness over time due to metabolic exhaustion, but we found a surprisingly simple approach to address it. 👇
https://t.co/WXN9834SbE
Ha distrutto le cellule tumorali presenti nei topi con la stessa efficacia ma senza attaccare anche quelle sane del sistema immunitario. E' la nuova terapia Car-T, che apre la strada verso futuri trattamenti senza effetti collaterali
@Penn@MyUniSR
https://t.co/cvt7WqbupT
A new design for #CARTcells that targets IGHV4-34 on B cell receptors can suppress lymphoma cells in vivo and neutralizes autoimmune #lupus B cells from patients, while avoiding off-target killing of healthy B cells. @MarcoRuella@PennCancer https://t.co/raplWkWK1S